Written questions by Davis.

What steps he is taking to encourage (a) the NHS, (b) Daiichi Sankyo, and (c) AstraZeneca to reach a commercial agreement that makes Enhertu available on the NHS in England.

Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.We know the NICE’s decision to not recommend Enhertu for use in the treatment of HER-2 low metastatic and unresectable breast cancer, has come as a blow to many women and their families. We understand that the NICE and NHS England have already sought to apply as much flexibility as they can in their considerations of Enhertu for HER2-low breast cancer and have made it clear to the companies that their pricing of the drug remains the main obstacle to access.The Government wants to see a deal reached to make Enhertu available. The NICE and NHS England remain open to considering an improved offer from the companies through the rapid review process, and we strongly encourage the companies to come back to the table.The NICE does recommend Enhertu (trastuzumab deruxtecan) in advanced breast cancer for treating HER2-positive unresectable or metastatic breast cancer after one or more anti-HER 2 treatments.

What estimate he has made of the amount of roof space in the UK that would be suitable for installing solar panels.

As part of our mission for clean power we will unleash a UK solar rooftop revolution, alongside accelerating energy efficiency improvements of the existing housing stock. Rooftop solar on new homes and buildings will, where appropriate, play an important role in the drive for solar, delivering cleaner energy and lower bills to millions of households and businesses. Future standards next year will set our new homes and buildings on a path that moves away from relying on volatile fossil fuels and ensures they are fit for a net zero future.

When the National Screening Committee will next review the potential merits of screening for prostate cancer.

The UK National Screening Committee’s (UK NSC) evidence review for prostate cancer screening is already underway, and plans to report within the UK NSC’s three-year work plan.The evidence review includes modelling the clinical cost effectiveness of several approaches to prostate cancer screening, including different potential ways of screening the whole population from 40 years of age onwards and targeted screening aimed at groups of people identified as being at higher than average risk, such as black men or men with a family history of cancer.